A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C

Stopped early · Not applicable

Conditions studied: Hepatitis C

In brief

The purpose of this pilot study is to learn whether high doses of ascorbic acid (vitamin c), given intravenously to patients with chronic hepatitis due to infection with the genotype 1 version of the hepatitis C virus, are safe, well-tolerated and able to reduce the amount of virus circulating in the patients' blood.

Key facts

Study ID

NCT01250743

Run by

Health Innovations, Frontier Research Institute

People needed

10

Starts

2009-01-01

Expected to finish

2012-06-01

Last updated by the study team

2011-02-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• hepatitis C, genotype 1
• failed treatment with interferon-alpha and ribavirin
• abstain from alcohol consumption for the duration of the study

You may not qualify if…

• cirrhosis
• decompensated liver disease
• glucose6phosphate dehydrogenase deficiency
• AST or ALT more than 5 times upper limit of normal
• platelets less than 125,000
• diabetes mellitus
• alcohol and/or drug abuse within 1 year of screening

Where it is running

• University of Kansas Medical Center, Department of Integrative Medicine — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.